BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-87562761 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-87562761\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06604715-3406@assetmemo.bio
DTSTAMP:20261121T010441Z
DTSTART;VALUE=DATE:20271103
DTEND;VALUE=DATE:20271104
SUMMARY:JNJ-87562761: Phase 1 readout est. (NCT06604715)
DESCRIPTION:JNJ-87562761\, phase 1\, Multiple Myeloma.\nStudy: A Study of J
 NJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma\n
 Estimated primary completion: 3 November 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/jnj-87562761#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06604715
URL:https://assetmemo.bio/drug/jnj-87562761#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
